The Global Diabetic Retinopathy Market size was USD 3.8 Billion in 2021 and is projected to reach USD 103.2 Billion by 2030, exhibiting a CAGR of 16.7% during the forecast period. Diabetic retinopathy is a medical condition that develops as a result of diabetic complications and is one of the primary causes of blindness. Diabetic retinopathy is determined by the type of diabetes a person has, the length of time they've had diabetes, and the level of blood sugar control they've achieved. Diabetic retinopathy symptoms include very minor to no symptoms at first, hazy and fluctuating vision, colour vision impairment, and eventually blindness. Diabetic retinopathy market expansion is predicted to be driven by rising diabetes incidence and occurrences of diabetes-related blindness. According to a 2017 report by the International Diabetic Federation, diabetes affects roughly 425 million persons aged 20 to 79. According to the International Agency for the Prevention of Blindness, one out of every three diabetics has a significant risk of developing diabetic retinopathy. Furthermore, according to a 2018 report published in The Lancet, the annual incidence of diabetic retinopathy worldwide ranges from 2.2 percent to 12.7 percent.
 

Blindness, cataracts, vitreous haemorrhage, glaucoma, and retinal detachment are some of the complications of diabetic retinopathy. Diabetic retinopathy is extremely curable; even people with advanced diabetic retinopathy have a 95% chance of keeping their vision before the retina is irreparably damaged. Diabetic retinopathy may be asymptomatic or cause relatively minor vision impairment. It can, however, result in blindness. Anyone with type 1 or type 2 diabetes can develop the illness. The longer a person has diabetes, the more likely they are to have ocular complications due to poorly regulated blood sugar. Diabetic retinopathy can progress to diabetic macular edoema, retinal detachment, and neovascular glaucoma, among other serious eye disorders.
 

The global diabetic retinopathy market is expected to suffer as a result of the COVID-19 epidemic. The global epidemic of COVID-19 has thrown healthcare workflows into disarray. As ophthalmological care is heavily reliant on specialised imaging equipment that is not widely available outside of ophthalmologists' offices, the shift to tele-ophthalmology visits was restricted.
 

Type Outlook

The diabetic macular edema (DME) segment is expected to dominate the market share in 2020 of global diabetic retinopathy market owing to rising geriatric population and the increasing occurrences of diabetes-related blindness are the main reasons for its large share. In addition, rising demand for frequent retinal screening among long-term diabetes patients is likely to drive category growth. rising prevalence of diabetic retinopathy, The rising prevalence of diabetes of all types, and the rising incidence of associated problems such as blindness.
 

The proliferative diabetic retinopathy is anticipated to emerge as the fastest-growing region of global diabetic retinopathy market over the forecast period. Fragile blood vessels form within the retina and vitreous humour in this case, causing impaired vision and blindness. It can cause macular edoema and has no symptoms in the beginning. Comprehensive eye exams, such as tonometry, visual acuity tests, and others, are used to diagnose it. It is treated with laser surgery, which causes the blood vessels to shrink.
 

Treatment Type Outlook

The anti VEGF drug segment is expected to dominate the market share in 2020 of global diabetic retinopathy market owing to commonly used to treat Proliferative Diabetic Retinopathy (PDR) (PDR). Anti-VEGF medicines were found to be more effective in PDR, particularly in situations of vitreous haemorrhage, neovascular glaucoma, and prior to vitrectomy.
 

The intraocular steroidal injection segment is anticipated to emerge as the fastest-growing region of global diabetic retinopathy market over the forecast period owing to intraocular steroidal injection is a relatively novel treatment for diabetic retinopathy and Diabetic Macular Edema (DME) that is steadily gaining traction. Corticosteroid-based medications are used in the injections to inhibit cellular growth. Triamcinolone (Durezol) has the best therapeutic performance of all the corticosteroids studied and has a large market presence. As retinopathy management tools, laser surgery and vitrectomy are included in other segments.
 

End User Outlook

The hospital segment is expected to dominate the market share in 2020 of global diabetic retinopathy market owing to surging laser surgical treatments are becoming more common. Furthermore, hospitals are well-equipped with diagnostic devices and technology. In addition, the government funds hospitals that are part of the public healthcare system. As a result, these hospitals will be able to finance the use of technologically advanced technology for ophthalmic surgery, which will benefit segmental growth.
 

Regional Outlook

North America is expected to dominate the market share in 2020 of global diabetic retinopathy market owing to the availability of modern healthcare infrastructure, favorable government activities relating to medication research, and a high degree of patient and practitioner knowledge are some of the market's drivers. Due to the presence of high unmet medical needs, rapidly rising patient awareness of effective diabetes diagnostic procedures, and rising healthcare expenditures.
 

The Asia Pacific segment is anticipated to emerge as the fastest-growing region of global diabetic retinopathy market over the forecast period owing to prevalence of diabetic retinopathy is quickly increasing, owing to rising disposable incomes and the development of healthcare infrastructures.
 

Key Companies & Recent Developments

Partnerships, strategic mergers, and acquisitions are expected to be the most successful strategies for industry participants to get speedy access to growing markets while also improving technological capabilities. For instance, in April 2019, Novartis received an approval for brolucizumab which will increase company’s product sales. In addition, product differentiation and developments, as well as service expansion, are projected to help organizations thrive in the market. For instance, in May 2019, Regeneron Pharmaceutical received the U.S. Food and Drug Administration (FDA) approval for EYLEA offering customize treatment as per patient need.
 

Market Segmentation of Global Diabetic Retinopathy Market

By Type

• Proliferative Diabetic Retinopathy
• Diabetic Macular Edema (DME)

By Treatment Type

• Anti VEGF Drug
• Steroid Implants
• Laser Surgeries
• Vitrectomy
• Intraocular Steroid Injection

By End User

• Hospitals
• Ophthalmic Centres
• Ambulatory Surgery Centres
• Others

Key Players

• Bayer AG
• Allergan plc
• Novartis AG
• Oxurion NV
• Sirnaomics Inc.
• Genentech
• Alimera Sciences
• Ampio Pharmaceuticals
• BCN Peptides
• Kowa Company, Ltd.